Agios Pharmaceuticals, Inc. (0HB0.L)

34,77 +0,27 (+0,79%) Ab 02:40PM BST. Markt geöffnet.

Agios Pharmaceuticals, Inc.

88 Sidney Street
Cambridge, MA 02139
United States
617 649 8600
https://www.agios.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 383

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Brian M. Goff M.B.A.	CEO & Director	1,46M	N/A	1969
Ms. Cecilia Jones	Chief Financial Officer	751,48k	N/A	1975
Mr. James William Burns	Corporate Secretary & Chief Legal Officer	1,02M	N/A	1978
Dr. Sarah Gheuens M.D., Ph.D.	Chief Medical Officer and Head of Research & Development	1,25M	N/A	1980
Ms. Tsveta Milanova	Chief Commercial Officer	939,05k	N/A	1977
Dr. Lewis Clayton Cantley Ph.D.	Co-Founder & Member of Scientific Advisory Board	50k	N/A	1949
Dr. Tak Wah Mak D.Sc., FRSC, Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1946
Dr. Craig B. Thompson M.D.	Co-Founder & Chairman of Scientific Advisory Board	N/A	N/A	1953
Dr. Shin-San Su Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	1956
Mr. T. J. Washburn	Principal Accounting Officer	N/A	N/A	1982

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Agios Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 5. Die grundlegenden Scores sind Audit: 6, Vorstand: 3, Shareholderrechte: 7, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.